Claims

1. Compound mixture, comprising 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide, or physiologically acceptable salts thereof, and an inhibitor of Her2, or physiologically acceptable salts thereof.

2. Compound mixture according to Claim 1, wherein the Her2 inhibitor is trastuzumab or lapatinib.

3. Pharmaceutical composition, comprising a compound mixture according to any of Claims 1 or Claim 2.

4. Pharmaceutical composition according to Claim 3, further comprising excipients and/or adjuvants.

5. The use of 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]quina- zoline-8-carboxylic acid amide, or physiologically acceptable salts thereof, and a Her2 inhibitor, or physiologically acceptable salts thereof in the manufacture of a medicament for the prophylaxis or treatment of human breast cancer.

6. The use according to Claim 5, wherein the 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)ethylamino]-quinazoline-8-carboxylic acid amide and the Her2 inhibitor are to be administered simultaneously.

7. The use according to Claim 5, wherein the 4-[(S)-2-Azetidin-l-yl-l-(4-chloro-3-trifluoromethyl-phenyl)ethylamino]quina-zoline-8-carboxylic acid amide and the Her2 inhibitor are to be administered sequentially.

8. The use according to Claim 5, wherein the Her2 inhibitor is to be administered first.